# Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

> **NCT04535414** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 195 (actual)

## Conditions studied

- Gastric Cancer
- Gastric Neoplasms
- Gastric Adenocarcinoma

## Interventions

- **DEVICE:** Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes
- **DEVICE:** Olympus Graphics Interchange Format (GIF) 190 endoscope
- **PROCEDURE:** Gastric mucosal biopsy

## Key facts

- **NCT ID:** NCT04535414
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-22
- **Primary completion:** 2024-09-12
- **Final completion:** 2025-01-10
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535414, "Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04535414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*